Zimmer Biomet (ZBH) Stock Forecast & Price Target

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

• Recent earnings results demonstrate strong fundamental performance, with the company reporting $2.07 earnings per share for the most recent quarter, which beat the consensus estimate of $2.01 by $0.06, while revenue of $2.18 billion also exceeded analyst expectations of $2.13 billion, indicating robust demand for its orthopedic products.
• The stock currently trades at $92.09, which is significantly below the consensus price target of $103.33, suggesting substantial upside potential as analysts maintain a "Hold" consensus rating with several firms, including UBS Group and Stifel Nicolaus, issuing "Buy" ratings with higher price targets.
• Zimmer Biomet Holdings, Inc. offers a stable income stream for investors through its dividend, which has a current yield of 1.08%, with a recent declaration of $0.24 per share quarterly, providing a consistent return on investment alongside potential capital appreciation.
• The company exhibits low volatility relative to the broader market, as indicated by a beta of 0.49, which means its stock price tends to fluctuate less than the overall market, making it a potentially defensive holding for investors seeking stability in the healthcare sector.
• Institutional investors continue to show confidence in the company, with major firms like BlackRock Inc. establishing new positions and State Street Corp increasing its holdings, reflecting a broader trend of institutional accumulation that often signals long-term value recognition.